MD Anderson Researchers Present Encouraging Results of Early-Stage Clinical Trials at 2022 ASCO Annual Meeting

June 7, 2022 10:45 am

by University of Texas M.D. Anderson Cancer Center

Newswise — CHICAGO ― Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for … Read more

First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD Status

June 6, 2022 9:30 am

by Ariana Pelosci

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

Rucaparib (Rubraca) significantly improved progression-free survival

Read more

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor

June 5, 2022 9:55 am

by Caroline Hopkins

CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.

The drug, which AstraZeneca licensed from Merck in … Read more

A Behind-the-Scenes Look at My Cancer Clinical Trial Experience

June 1, 2022 11:07 am

by Kelly Irvin

It’s good to have all the facts when you decide whether to participate in a cancer drug clinical trial—even the ones that make you swallow hard and tear up.

To find clinical trials, please check out the Read more

First-line Niraparib Improves PFS in Ovarian Cancer

May 18, 2022 9:16 am

by Ariana Pelosci

An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.

An

Read more

MEK Inhibition Is Now a Standard of Care in Recurrent Low-Grade Serous Ovarian Cancer: What Next?

April 25, 2022 12:08 pm

by Rachel N. Grisham, M.D.

As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more

Early Signs of Clinical Promise Noted for Neoadjuvant Chemoimmunotherapy in Advanced Ovarian Cancer

April 13, 2022 2:12 pm

by Conor Killmurray

Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.

The use of dual immune checkpoint

Read more

Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11, 2022 9:46 am

by Jonah Fieldman

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results, according to data

Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

SORAYA Trial: Antibody-Drug Conjugate Produces Remissions in One-Third of Patients With Drug-Resistant Ovarian Cancer

March 22, 2022 10:22 am

by the ASCO Post Staff

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel antibody-drug conjugate therapy produced a substantially better response than standard treatments, investigators from Dana-Farber Cancer Institute reported at the … Read more

Intraperitoneal Carboplatin Plus Paclitaxel Improves PFS in Ovarian Cancer, Yet OS Results Remain Unchanged Vs IV Chemo

March 20, 2022 10:18 am

by Gina Mauro

The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.

The use

Read more

Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer

March 20, 2022 9:55 am

by Hayley Virgil

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses

Read more

New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer

February 14, 2022 10:17 am

by Anne Doerr

A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more

Industry News: Ovarian cancer therapy boosted by drug that slows disease’s advance

February 4, 2022 9:28 am

A drug currently used to treat skin and lung cancers has been found to slow the progression of a form of ovarian cancer and increase the number of patients who respond to treatment, a clinical trial has found.

As a … Read more

My Experience Enrolling in a Cancer Clinical Trial: The Verdict Is ‘Yes’

January 26, 2022 10:19 am

by Julie S. Brokaw

A patient with ovarian cancer describes how she enrolled in a clinical trial, and how it has given her a renewed sense of hope that she may find a successful treatment option.

To find clinical trials,

Read more

Paclitaxel Plus Carboplatin Is Reportedly Non-Inferior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma

January 13, 2022 8:49 am

by Ariana Pelosci

Findings from a phase 3 study indicated that patients with uterine carcinosarcoma treated with paclitaxel and carboplatin experienced a better progression-free survival and non-inferior duration of overall survival vs paclitaxel plus ifosfamide.

A combination regimen of paclitaxel

Read more

STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer

January 7, 2022 11:18 am

by Kristi Rosa

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced

Read more

Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer

November 30, 2021 12:10 pm

by Nichole Tucker

Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.

Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant

Read more

Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer

November 17, 2021 10:25 am

By Courtney Marabella

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.

The addition of a short-term,

Read more